Clinical trials: Host vs Graft Reaction
Acute Graft Versus Host Disease
Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
This research trial is designed to study the safety and effectiveness of combining the study drug, Natalizumab (Tysabri®) with the standard treatment, the use of steroids, as a new treatment for acute graft versus host disease…
- Trial name
- NCT02133924
- Testing
- natalizumab, steroids
- Where
- 12 sites in United States
- Volunteers
- 76 people
- Sponsor
- John Levine
COVID-19 Disease
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection
A Phase II Randomized, double-blind, Placebo-controlled Study to Evaluate the safety and efficacy of exosomes overexpressing CD24 to prevent clinical deterioration .The study population will include patients with moderate or…
- Trial name
- NCT04969172
- Testing
- Exosomes overexpressing CD24
- Where
- Israel
- Volunteers
- 155 people
- Sponsor
- Eli Sprecher, MD
Acute-graft-versus-host Disease, Steroid Refractory Acute Graft Versus Host Disease
Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)
An Early Access Program for patients with steroid refractory acute GvHD after hematopoietic stem cell transplantation. This Program is available for female and male who are recipients of allogenic HSCT and who have been newly…
- Conditions
- Acute-graft-versus-host Disease, Steroid Refractory Acute Graft Versus Host Disease, Graft-versus-host-disease, Graft Vs Host Disease
- Trial name
- NCT03172455
- Testing
- Glassia
- Sponsor
- Impatients N.V. trading as myTomorrows
Liver Failure, Liver Diseases
Everolimus in de Novo Liver Transplantation: a Multicentre Randomized Study
Safety and Efficacy of Everolimus in adult de novo liver transplant recipients.
- Conditions
- Liver Failure, Liver Diseases, Liver Cirrhosis, Liver Neoplasms
- Trial name
- EPOCAL (NCT01423708)
- Testing
- Everolimus
- Where
- 7 sites in Italy
- Volunteers
- 117 people
- Sponsor
- Azienda Ospedaliera di Padova
Alcohol Use Disorder (AUD), Alcoholism
Cue Effects in Human Addiction: Pavlovian to Instrumental Transfer
Individuals with substance use disorders (SUD) have to cope with drug-related cues and contexts, which can affect instrumental drug seeking as shown with Pavlovian to instrumental transfer (PIT) paradigms in animals and humans.
- Conditions
- Alcohol Use Disorder (AUD), Alcoholism, Substance Use Disorders, Smoking, Tobacco
- Trial name
- ReCoDe (NCT05992272)
- Testing
- fMRI imaging (BOLD), sMRI (structure), Trier Social Stress Test
- Where
- 2 sites in Germany
- Volunteers
- 300 people
- Sponsor
- Charite University, Berlin, Germany
Allogeneic Disease, GVH - Graft Versus Host Reaction
To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids
Phase III randomized double-blinded trial designed to compare the efficacy of the addition of MTX to current standard acute GVHD first-line treatment with corticosteroids.
- Conditions
- Allogeneic Disease, GVH - Graft Versus Host Reaction, GVHD, Acute, Stem Cell Transplant Complications
- Trial name
- MTX-aGVHD (NCT03371667)
- Testing
- Methotrexate
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Graft Versus Host Disease, Hematologic Malignancy
Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis
This is a two arm open label phase III clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from any donor are eligible for the study if they meet the standard criteria defined in the…
- Conditions
- Graft Versus Host Disease, Hematologic Malignancy, Cyclophosphamide Adverse Reaction
- Trial name
- CY25 (NCT05158608)
- Testing
- Post-transplantation Cyclophosphamide at dose 25 mg/kg/day, Post-transplantation Cyclophosphamide at dose 50 mg/kg/day
- Volunteers
- 100 people
- Sponsor
- National Research Center for Hematology, Russia
Kidney Transplantation, Transplantation Immunology
A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients
The purpose of this study is to compare the efficacy and safety of Prograf extended release(XL) plus MMF with Prograf plus MMF in de novo kidney transplant recipients.
- Conditions
- Kidney Transplantation, Transplantation Immunology, Host vs Graft Reaction
- Trial name
- NCT00717678
- Testing
- Prograf-XL, Prograf, MMF
- Where
- 5 sites in Taiwan
- Volunteers
- 73 people
- Sponsor
- Astellas Pharma Inc
Kidney Transplantation, Host vs Graft Reaction
Renal Transporters After Renal Transplantation
Previous studies in animals revealed, that the activity of certain transporters along the nephron is changed with acute rejection after renal transplantation.
- Trial name
- NCT00427024
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- University Hospital Muenster
Liver Transplantation, Transplantation Immunology
A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.
The purpose of this study is to compare the efficacy and safety of Prograf extended release(XL) plus MMF with Prograf plus MMF and steroid withdrawal in de novo Liver transplant recipients
- Conditions
- Liver Transplantation, Transplantation Immunology, Host vs Graft Reaction
- Trial name
- NCT00720408
- Testing
- Prograf-XL, Prograf, MMF
- Where
- 4 sites in Taiwan
- Volunteers
- 48 people
- Sponsor
- Astellas Pharma Inc